January 18, 2017
1 min read

Beta-blockers may lower mortality, but not hospitalization in patients with HF, AF

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In patients with HF and atrial fibrillation, beta-blockers are associated with significantly lower mortality but not hospitalization, regardless of the pattern or burden of atrial fibrillation, new data show.

Julia Ca drin-Tourigny, MD, of the Montreal Heart Institute at Université de Montréal, and colleagues studied patients with both AF and HF with reduced ejection fraction to analyze the effect beta-blockers had on all-cause mortality, CV mortality and hospitalization.

Of the 1,376 participants (mean age, 70 years; 81% men; mean left ventricular EF, 27%), 79% (n = 1,085) received beta-blockers. For those who did not receive beta-blockers, the reasons given were physician preference (42%), pulmonary disease (24%), intolerance (18%) and other (6%). The cohort was propensity-matched.

Through a median follow-up of 37 months, 35% of patients died (n = 231), 42% of those without beta-blockers (n = 95) and 31% of those with beta-blockers (n = 136).

Beta-blockers were associated with a significantly lower risk for mortality (HR = 0.721; 95% CI, 0.549-0.945), according to the researchers. Although not significant, beta-blockers were associated with fewer hospitalizations (HR = 0.886; 95% CI, 0.715-1.1).

When the researchers modeled beta-blockers as a time-dependent variable, similar results occurred (all-cause mortality HR = 0.668, 95% CI, 0.511-0.874; hospitalizations HR = 0.814; 95% CI, 0.653-1.014).

Additionally, no significant interactions were found between beta-blockers and burden or pattern of AF.

The limitations of the study included its retrospective nature, not recording the agent and dose of beta-blockers, and the study population being limited to patients with HFrEF and nonpermanent AF at baseline, Cadrin-Tourigny and colleagues wrote.

“Notwithstanding the acknowledged limitations and the smaller sample size, our results challenge a contemporary patient-level meta-analysis and lend credence to current guidelines, which recommend beta-blockers for patients with [HFrEF], without distinguishing between those with or without AF,” the researchers wrote. – by Cassie Homer

Disclosures: The researchers report no relevant financial disclosures.